Paper Details

  1. Home
  2. Paper Details

The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring.

Author: BarreiroPablo, BlancoFrancisco, Gonzalez-PardoGema, González-LahozJuan, Jiménez-NácherInmaculada, MorelloJudit, Rodríguez-NovoaSonia, SorianoVincent, VispoEugenia

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tipranavir is a potent protease inhibitor but has a high pill burden and frequent side effects. This study found that reducing the ritonavir dose in patients taking tipranavir/ritonavir resulted in decreased liver enzymes and cholesterol levels in some patients without affecting viral suppression.
Paper Details　
Original Abstract of the Article :
Despite being among the most potent protease inhibitors, the use of tipranavir (TPV) is hampered by a high pill burden and frequent side effects compared with other boosted protease inhibitors. A total of 10 patients receiving TPV/ritonavir (TPV/RTV) 500/200 for longer than 6 months were randomized ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/FTD.0b013e3181d3f97f

データ提供：米国国立医学図書館（NLM）

Simplifying Treatment Regimen for Tipranavir: Therapeutic Drug Monitoring Guides Dosage Optimization

This study explores the potential benefits of simplifying the treatment regimen for tipranavir (TPV), a potent protease inhibitor used in HIV treatment. The researchers evaluated the efficacy and safety of reducing the ritonavir (RTV) boosting dose from 200 mg to 100 mg in patients receiving TPV/RTV 500/200.

Tipranavir: Balancing Potency with Tolerability

The study showed that reducing the RTV boosting dose to 100 mg was safe and effective, maintaining viral suppression while potentially improving tolerability. The researchers observed a reduction in aminotransferases and total cholesterol in some patients, suggesting potential benefits of the simplified regimen.

HIV Treatment: Optimizing Regimen for Better Outcomes

This research highlights the importance of individualized treatment approaches in HIV management. The study's findings suggest that therapeutic drug monitoring can guide dosage optimization, potentially improving treatment tolerability and patient adherence to medication regimens.

Dr. Camel's Conclusion

Just like a camel navigating the vast desert, HIV patients need to find a treatment strategy that is both effective and manageable. This study provides valuable insights into the potential benefits of simplifying tipranavir treatment regimens, paving the way for improved tolerability and adherence to medications.

Date :
  1. Date Completed 2010-11-05
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

20216112

DOI: Digital Object Identifier

10.1097/FTD.0b013e3181d3f97f

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.